Recombinant rsv virus expression systems and vaccines
CA 2380108 C · Owner: Tang, Roderick · Inventors: Jin, Hong; Bryant, Martin; Li, Shengqiang
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2 NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition the , present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 2, 2000 and granted October 15, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 2, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 2, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.